Drugs / SF2a-TT15
SF2a-TT15
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02797236 | Sep 2016 → Jun 2017 | shigellosis | Institut Pasteur | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT04602975 | Oct 2020 → Apr 2023 | — | Institut Pasteur | Completed | No outcome recorded |
| Phase 2 | NCT04078022 | Mar 2020 → Jan 2023 | shigellosis | University of Maryland, Baltimore | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SF2a-TT15 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04602975 ↗ |
| Known as | SF2a-TT15 glycoconjugate | “The SF2a-TT15 glycoconjugate was well tolerated at both doses.” PMID 33186516 ↗ Nov 2020 |
| Known as | SF2a-TT15 vaccine | “SF2a-TT15 vaccine candidate” PMID 33186516 ↗ Nov 2020 |
| Known as | Shigella flexneri 2a-Tetanus Toxoid15 (SF2a-TT15) | “The purpose of this study is to examine the safety and immunogenicity of two doses of the parenteral synthetic carbohydrate-based conjugate vaccine against Shigella flexneri 2a...” NCT04602975 ↗ |
| Modality | Vaccine | “synthetic carbohydrate conjugate vaccine” PMID 33186516 ↗ Nov 2020 |
| Route | Intramuscular | “The vaccine was administered as three single intramuscular injections into the arm” PMID 33186516 ↗ Nov 2020 |